Northwest Biotherapeutics, Inc. (NWBO) Partners with King’s Health Partners to Benefit Ongoing Clinical Trial
Northwest Biotherapeutics, a biotech company focused on the development of immunotherapy products for the treatment of cancers, today announced its partnership with King's Health Partners, in which the companies will manufacture and deliver a new treatment for patients with brain cancer as part of its ongoing 240-patient clinical trial for Glioblastoma multiforme (GBM), the most fatal form of brain cancer. Per the arrangement, specialists at King's College London will manufacture Northwest’s immune therapy treatment, DCVax®, for the clinical trial, which will take place at King's College Hospital NHS Foundation Trust in London. Among several anticipated benefits, the collaboration generates additional…